NervGen Pharma Corp. (NGEN)

NervGen Pharma Corp. (NGEN) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $166M; returns 1 day +0.7%, 1 week -10.1%.

NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on neuroreparative medicine, specifically developing treatments to restore function in patients with nervous system damage. As of April 2026, the company operates as a pre-revenue entity, with its economic value entirely driven by its lead drug candidate, NVG-291.

Groups NGEN belongs to

• Recent IPOs
• Canada Companies
• Clinical Stage Biopharma
• Biotechnology
• Biopharmaceutical
• Neuroscience
• Clinical Stage Biotech
• Regenerative Medicine
• Healthcare
• Neurological Disorders
• Life Sciences
• CNS Disorders
• R&D

NGEN financial model: income statement, cash flow and balance sheet